Study Comparing the Efficacy of Peripherally Inserted Central Catheter (PICC) Placement With the Addition of Cyanoacrylate Glue Versus PICC Placement Alone in Patients With Cancer. (PICCandGLUE)

September 6, 2023 updated by: Centre Leon Berard

Randomized, Prospective, Single-center Trial Comparing the Efficacy of Peripherally Inserted Central Catheter (PICC) Placement With the Addition of Cyanoacrylate Glue Versus PICC Placement Alone (Without Glue) in Patients With Cancer.

This is a randomized, prospective, single-center trial comparing the efficacy of peripherally inserted central catheter (PICC) with the addition of cyanoacrylate glue versus PICC placement alone (without glue) in cancer patients.

Study Overview

Status

Recruiting

Conditions

Detailed Description

Peripherally Inserted Central Catheters (PICCs) are a form of vascular access inserted percutaneously into a vein, usually in the arm, with the distal end at the atrio cava junction (between the superior vena cava and the right atrium). They may be used for a prolonged period or for several days, repeatedly over time (as is the case for certain chemotherapies, parenteral nutrition or long-term intravenous treatments).

Their placement requires aseptic surgical conditions, and a team trained in the procedure, sometimes grouped together in a Vascular Access Unit (UAV).

A PICC is inserted by puncturing the skin and subcutaneous tissues, and securing the catheter with a "Statlock" type stabilizer. The catheter exit point must be covered, at a minimum by a sterile occlusive dressing with a transparent semi-permeable membrane, otherwise referred to as a "transparent dressing".

According to available data, tissue puncture results in bleeding at the puncture site in 25% to 40% of procedures. This bleeding necessitates the application of a sterile compress prior to covering with a transparent dressing. The skin puncture site (also known as the catheter exit point) requires the dressing to be repeated on D1 after insertion.

To sum up:

  • If there is no bleeding, there is no need to apply a compress, and the dressing can be changed on D8 after application;
  • In the presence of bleeding, a compress is applied and dressing change is mandatory on D1 after application.

PICC placement combined with the use of cyanoacrylate glue would reduce the risk of bleeding, and therefore the need to use of a compress, compared with a standard procedure (without the use of glue).

On this basis, the investigators propose to conduct a randomized, prospective, single-center trial comparing the efficacy of peripherally inserted central catheter (PICC) with the addition of cyanoacrylate glue versus PICC placement alone (without glue) in patients with cancer.

Study Type

Interventional

Enrollment (Estimated)

98

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Lyon, France
        • Recruiting
        • Centre Léon Bérard
        • Contact:
          • Grégoire WALLON, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Male or female, 18 years of age or older on the date of signature the informed consent form
  • Patient with a histological diagnosis of cancer
  • Indication for central line chemotherapy or immunotherapy
  • Placement of a single-lumen PICC in the non-tunneled upper limb planned on an ambulatory basis at the Centre
  • Planned duration of PICC use > 30 days
  • Dated and signed informed consent, indicating that the patient has been informed of all relevant aspects of the study prior to inclusion;
  • Patient covered by a health insurance plan

Exclusion Criteria:

  • Patient already included in the study ;
  • Patient with known allergy to cyanoacrylates, Violet D&C or formaldehyde;
  • Patient not reachable by telephone ;
  • Patient under guardianship;
  • Patient does not speak French.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: PICC placement according to standard practice + cyanoacrylate glue

PICC placement will be performed according to standard practice (Safe Insertion of PICC protocol (SIP2) steps).

The catheter will be secured by the Statlock system. Cyanoacrylate glue will be applied on the catheter exit point in accordance with the instructions for use.

A transparent dressing will be applied, with a compress in the event of bleeding.

The wound must be positioned in a horizontal plane, and the glueapplied uniformly overhanging the wound. Cyanoacrylate glue is contraindicated when adhesion cannot be achieved.

Cyanoacrylate glue should be applied in accordance with the instructions for use.

Wound-closing properties are only fully achieved once the first layer has fully polymerized. This depends on skin type, skin hydration and ambient humidity. If a second layer is applied, the polymerization time is extended accordingly.

No Intervention: PICC placement according to standard practice

PICC placement will be performed according to standard practice (Safe Insertion of PICC protocol (SIP2) steps).

The catheter will be secured by the Statlock system. A transparent dressing will be applied, with a compress in the event of bleeding.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Rate of patients with successful PICC placement
Time Frame: Hour 0
Success is defined by the possibility of using a dressing without compression at application (at hour 0), i.e. without bleeding after the defined compression time.
Hour 0

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Proportion of dressing changes within one hour
Time Frame: Up to hour 1
Proportion of patients requiring dressing changes at the CLB within one hour of the end of procedure
Up to hour 1
Proportion of dressing changes before day 8
Time Frame: Up to day 8
Proportion of patients requiring dressing changes (home nursing/home care/home hospitalization) in the medium term (day 8)
Up to day 8
Proportion of dressing changes before day 30
Time Frame: Up to day 30
Proportion of patients requiring dressing changes (home nursing/home care/home hospitalization) in the medium term (day 30)
Up to day 30
Incidence of PICC removal before day 30
Time Frame: Up to day 30
Incidence of PICC removal for any reason within 30 days following placement.
Up to day 30
Incidence of PICC-related complications before day 30
Time Frame: Up to day 30
Incidence of PICC-related complications (infection, thrombotic event, obstruction, displacement requiring PICC replacement or not) in the 30 days following placement.
Up to day 30

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Grégoire WALLON, MD, Centre Léon Bérard

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 2, 2023

Primary Completion (Estimated)

November 15, 2023

Study Completion (Estimated)

December 15, 2023

Study Registration Dates

First Submitted

July 5, 2023

First Submitted That Met QC Criteria

July 12, 2023

First Posted (Actual)

July 13, 2023

Study Record Updates

Last Update Posted (Actual)

September 7, 2023

Last Update Submitted That Met QC Criteria

September 6, 2023

Last Verified

September 1, 2023

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cancer

Clinical Trials on Cyanoacrylate glue application

3
Subscribe